Spencer S. Eccles Health Sciences Library, University of Utah
Abstract
Infliximab is a tumor necrosis factor blocker that has been approved for the treatment of Crohn's disease and rheumatoid arthritis. A single case of retrobulbar optic neuritis associated with Infliximab has been recently reported. In this case the patient developed a superior visual field defect
